Press Releases

February 17, 2021
Drug Delivery Experts Obtains FDB License for Manufacture of Sterile Injectable Clinical Trial Materials

February 24, 2020
Determination of the Ability of a Novel, Long-Acting (3 Months) Subcutaneous GnRH Antagonist, VERU-100, to Castrate Without a Testosterone Surge in a Rat Model

June 4, 2019
Veru, in Collaboration with DDE Labs, Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to Its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA

August 28, 2018
Drug Delivery Experts and Baywind Bioventures Announce Patent Applications in Biopolymer Salts and Oral Delivery

May 23, 2018
Drug Delivery Experts Provide Highlights from Peptide Research in Chemistry Today

March 1, 2018
Drug Delivery Experts CEO Chris Rhodes Presenting at AsiaTIDES

November 8, 2017
Drug Delivery Experts CEO Chris Rhodes Presents at EuroTIDES

October 11, 2017
Drug Delivery Experts CEO Chris Rhodes Presents at the 5th CPC Symposium

July 11, 2017
Drug Delivery Experts Expands Capabilities in Strategic Partnership with KYDES Pharmaceuticals

July 11, 2017
Drug Delivery Experts CEO Chris Rhodes Presenting at the 44th Meeting & Exposition of the Controlled Release Society

July 1, 2017
CEO Chris Rhodes quoted in GEN News article 

June 9, 2017
CEO Chris Rhodes and Luke Remley appear on Drew Shlosberg’s U~T San Diego Community Spotlight Radio Show

June 1, 2017
Drug Delivery Experts strengthens leadership with Rob Jennings, COO

May 2, 2017
Drug Delivery Experts and Protea Biosciences at PEGS BOSTON 2017

July 1, 2016
Chris Rhodes quoted in GEN News article “Peptide Therapies are Due for a Gut Check”

May 6, 2016
Drug Delivery Experts moves to new location, located at 11494 Sorrento Valley Road, Suite J.

January 26, 2015
Drug Delivery Experts and Sensulin highlighted as entrepreneurs are moving companies into San Diego.

October 8, 2014
Portage announces additional consultants to expedite its PPL-003 development programs.

June 20, 2014
Drug Delivery Experts opens R&D laboratory in San Diego, CA, and announces Sensulin as first co-located company and partner for virtual R&D.


Winter 2021

Fall 2020

Summer 2020

Spring 2020

Fall 2019


Biocom’s Lifelines Fall 2019: Developing Novel Delivery Technologies for Unmet Medical Needs


Oral Delivery of Biologics

Complex Generics

Long-Acting Injectables & Implantables

Case Studies

Peptide Lead Selection

Peptide Salt Screening

Liposome Delivery

Peptide ANDA

SR Gel Formulation

Pegylation of Therapeutic Protein

Injection Site Reaction


Exenatide and Its Life Cycle PBSS San Francisco February 2020

Peptide Delivery System Update CPC Symposium 2019

Long-Acting Injectables and Implantables Overview CRS 2019

Oral Peptide Delivery Update AsiaTIDES 2018

Formulation Challenges and Opportunities for Peptide Drug Product CPC Symposium 2017

Sequencing a Polyethylene Glycol Conjugation Site PEGS 2017 

Increasing Peptide Plasma Exposure Time CRS 2017

Peptide Sustained Release AsiaTIDES 2017

Oral Peptide Delivery TIDES 2016

Delivery Technology and Clinical Development Panel CRS 2015

Transdermal and Glucose Sensing 2015

Case Study on Injection Site Precipitation TIDES 2015

Peptide Formulation TIDES 2015

Update on Non-Invasive Peptide Delivery TIDES 2014

Development of an Active Transdermal System, DDP 2014

Practical Considerations for Alternate Delivery of Proteins, PepTalk 2013

Peptides in Clinical Development, CACO 2012

Application of Sustained Release Technology for Back of the Eye Disease, Drug Delivery and Formulation Summit 2012

Controlled Delivery of Biologics, AAPS National Biotech Conference 2009

Transdermal Exenatide Delivery in Patients with Type 2 Diabetes: PKPD, Diabetes Technology Society 2011

Revisiting the Therapeutic Potential of Leptin, AAPS National Biotechnology Conference 2011

Improving Physicochemical Properties of Biopharmaceutical Drug Candidates, PEGS Conference 2010

Intranasal administration of exenatide in Type II diabetic patients, ADA 2008